The impact of para-aortic lymph node irradiation on disease-free survival in patients with cervical cancer: A systematic review and meta-analysis

Leslie J.H. Bukkems a, Ina M. Jürgenliemk-Schulz a,*, Femke van der Leij a, Max Peters a, Cornelis G. Gerestein b, Ronald P. Zweemer b, Peter S.N. van Rossum b, a

* Corresponding authors at: Department of Radiation Oncology, Q00.3.11, University Medical Center Utrecht, PO Box 85000, 3508GA Utrecht, The Netherlands. E-mail addresses: J.M.Schulz@umcutrecht.nl (J.M. Jürgenliemk-Schulz), P.S.N.vanRossum-2@umcutrecht.nl (P.S.N. van Rossum).

Keywords: Cervical cancer Chemoradiotherapy Para-aortic radiotherapy Disease-free survival Meta-analysis

ABSTRACT

Background: Patients with locally advanced cervical cancer without para-aortic lymph node metastases (PAO-LNM) at diagnosis who undergo concurrent chemoradiotherapy are at 4–11% risk of developing PAO-LNM during follow-up. Some studies suggest a beneficial influence of elective para-aortic radiotherapy (PAO-RT) on disease-free survival (DFS) in these patients. The aim of this study was to systematically review and meta-analyse literature on the impact of PAO-RT on DFS in cervical cancer patients.

Methods: A systematic search of PubMed/MEDLINE and EMBASE databases was performed. The analysis included intervention studies that reported on DFS in patients with cervical cancer who received chemoradiotherapy and pelvic radiotherapy with or without PAO-RT. From each included study, relevant study characteristics and outcome data including the hazard ratio (HR) adjusted for potential confounders were extracted. An overall pooled adjusted hazard ratio (aHR) for DFS after PAO-RT versus no PAO-RT was calculated using a random-effects model.

Results: A total of 2,016 articles were evaluated. Eleven articles were included in the systematic review, of which 3 were appropriate for quantitative meta-analysis. Pooling of these 3 cohorts (including 1,113 patients) demonstrated a statistically significant association between PAO-RT and DFS (pooled aHR 0.87, 95% confidence interval: 0.79–0.97). No significant heterogeneity among reported aHRs was observed ($I^2 = 0.0\%$).

Conclusions: This meta-analysis suggests a modest but significant beneficial impact of elective para-aortic radiotherapy on DFS in patients with locally advanced cervical cancer who undergo concurrent chemoradiotherapy. This finding based on non-randomized studies provides an imperative for further investigation in prospective controlled trials.

Introduction

Although screening has led to a major decline in the number of cases, uterine cervical cancer remains the fourth most common cancer in women [1]. Lymph nodes play an important role in the metastatic progression of cervical cancer and the presence of lymph node metastasis is the single most important prognostic factor [2]. Lymphatic spread often follows a predictable order, starting at the regional pelvic lymph nodes, followed by the para-aortic lymph nodes and, finally, distant metastases [3]. The para-aortic lymph nodes are also a common site for disease recurrence after pelvic radiotherapy with concurrent chemotherapy for locally advanced cervical cancer [4–6].

At diagnosis, approximately 25–47% of patients with cervical cancer have pelvic lymph node metastasis, whereas 4–8% of patients present with para-aortic lymph node metastases (PAO-LNM) [7–9]. Patients with pelvic lymph node metastasis are at increased risk of developing para-aortic lymph node metastases (PAO-LNM) [5,7]. In fact, the multicenter EMBRACE (intErnational MRI-guided BRachytherapy in CErvicical cancer) study group showed that in patients with pelvic nodal metastases at diagnosis the risk of developing PAO-LNM during follow-up is 11%, as opposed to 4% in patients with cN0 disease at diagnosis [8,10]. Also, the RetroEMBRACE and EMBRACE-I studies indicated that para-aortic failure is the major challenge for nodal control [11].

Para-aortic lymph node metastases are generally assessed with magnetic resonance imaging (MRI) and/or $^{18}$F-fluordeoxyglucose positron emission tomography with integrated computed tomography ($^{18}$F-FDG PET-CT).
However, with these imaging modalities occult PAO-LNM may be missed in a considerable amount (12%) of patients [12]. In patients with suspicious pelvic lymph nodes, the false-negative rate of imaging for PAO-LNM is as high as 22% (versus 9% in patients without suspicious pelvic lymph nodes) [13]. Therefore, in patients without evidence of PAO-LNM, extending the standard pelvic radiation field to cover the para-aortic lymph node area is sometimes considered to treat potentially present occult PAO-LNM. A recent analysis from the multicenter EMBRACE study group showed that the addition of elective para-aortic radiotherapy (PAO-RT) was associated with significantly less para-aortic nodal failure, especially in patients with pelvic lymph node metastases [10]. No information on disease-free survival (DFS; including recurrences other than PAO-LNM) was provided in that study. The disadvantage of adding PAO-RT is the increased risk of complications, such as enteritis, diarrhea, and myelosuppression, compared to pelvic radiotherapy only [14,15].

Before concurrent chemotherapy became a standard addition to radiotherapy, patients with locally advanced cervical cancer received definitive radiotherapy alone. In 1995, the Radiation Therapy Oncology Group (RTOG) reported that prophylactic PAO-RT was associated with improved survival rates [16]. However, in the current era of concurrent chemoradiotherapy in which chemotherapy also targets occult metastatic disease, as supported by the observed association between the number of chemotherapy cycles and metastasis-free survival [17,18], the role of elective PAO-RT has become more controversial. Therefore, the aim of this study was to systematically review and meta-analyse the available literature on the impact of adding elective PAO-RT to standard pelvic radiotherapy on disease-free survival (DFS) in patients with locally advanced cervical cancer and pelvic lymph node involvement who are treated with concurrent chemoradiotherapy.

Methods

This review has been registered in the PROSPERO international database of prospectively registered systematic reviews, accessible at https://www.crd.york.ac.uk/prospero/ with registration number CRD42021275325. This study was reported according to the PRISMA 2020 guideline for reporting systematic reviews [19].

Search strategy

A systematic literature search was conducted and last updated on 5 November 2021 to identify all studies from the year 1995 onwards reporting on PAO-RT and DFS or overall survival (OS) in patients with locally advanced cervical cancer. The year 1995 was chosen as this was the publication year of the long-term results of the key RTOG-7920 trial on PAO-RT [16] and studies before that date were considered to have low generalizability due to outdated staging and treatment techniques. The search terms ‘cervix’, ‘cancer’, ‘para-aortic’, ‘radiotherapy’, and synonyms, were used to search Embase and PubMed/MEDLINE databases according to the search strategy presented in Table 1.

Study selection

After removal of duplicates, all titles and abstracts were evaluated for eligibility. Any citation considered potentially relevant was retrieved for full text review. Full texts of potentially relevant articles were then evaluated for inclusion.

Eligibility criteria included studies that reported on radiotherapy of para-aortic lymph nodes or extended field radiotherapy in cervical cancer patients with pelvic lymph node metastases, that provided data on DFS and/or OS. At least 1 patient should have had pelvic lymph node metastases in both the group with PAO-RT and the group without PAO-RT. Subsequently, studies in which patients received no concurrent chemotherapy were excluded, as well as reviews, editorials, letters to the editor, conference abstracts and case reports, and studies with less than 5 cervical cancer patients. In case multiple articles showed significant overlap, only the article describing the largest study population was included. Publications written in languages other than English or Dutch were excluded. Finally, reference lists of included articles were screened for other potentially relevant articles.

Data extraction and quality assessment

From each included study, relevant treatment and outcome data and study characteristics were extracted. Information on the author, year of publication, country, study design, number of participants, International Federation of Gynaecology and Obstetrics (FIGO) tumour stage, age of the patients, lymph node metastasis, treatment regimen, follow-up duration and survival data were captured. DFS in the studies was defined as the time after primary treatment that the patient survived without recurrence of disease in any location (i.e. local, regional or distant). In accordance with recent large-scale data from EMBRACE, reported 5-year DFS rates in the studies were expected to be in the order of 65–70% [20].

The primary outcome measure was the hazard ratio (HR) for DFS after PAO-RT versus no PAO-RT that in case of non-randomized studies had to be adjusted for potential confounders in either propensity score matching, inverse probability treatment weighting (IPTW) or multivariable analysis. This adjusted HR (aHR) was chosen in accordance with the Cochrane Handbook for Systematic Reviews recommendations [21], because this represents the least biased within-study estimate of the DFS impact of PAO-RT (in contrast to unadjusted HR or crude survival point estimates). Overall survival (OS) was not chosen as primary outcome as –compared to DFS– it was considered a more indirect outcome of extending versus not extending the radiation field to PAO lymph nodes, with DFS being the more direct potentially affected outcome. Study quality and possible bias of articles included in the meta-analysis were assessed using the Cochrane Risk Of Bias In Non-randomized Studies of Interventions tool (ROBINS-I) [22] and visualized using the associated risk-of-bias visualization tool (robvis) [23].

Statistical analysis

Reported independent associations between PAO-RT and DFS, expressed as aHRs with 95% confidence intervals (95% CIs), were pooled using a random-effects model. Heterogeneity across aHRs of individual studies was assessed using the I² statistic. An I² between 30 and 60% was considered moderate heterogeneity according to the Cochrane Handbook for Systematic Reviews [24]. The number of studies was insufficient for properly powered subgroup analyses or meta-regression. A sensitivity analysis was performed through exclusion of 1 study from

Table 1

| No. | Search query                                                                 | PubMed  | Embase   |
|-----|------------------------------------------------------------------------------|---------|----------|
| #1  | Cancer OR carcinoma OR tumor OR tumour OR malignant OR neoplasm              | 4,635,340| 6,348,518|
| #2  | Radiotherapy OR radiation OR irradiation OR X-ray therapy                    | 724,640 | 1,109,237|
| #3  | Cervical OR cervix                                                          | 280,564 | 277,381  |
| #4  | Para-aortic OR paraaortic OR peri-aortic OR periaortic OR PALN OR retroperitoneal | 38,290  | 64,827   |
| #5  | #1 AND #2 AND #3 AND #4                                                    | 1,022   | 2,138    |
the meta-analysis to determine the effect on the overall pooled aHR.

In the synthesis of all the studies (including those with no reported aHR), 3-year and 5-year DFS and OS estimates were summarized as median values as well as mean values weighted for study sample size. Importantly, these summary estimates represent crude (univariable) survival estimates that were not adjusted for confounders, and should therefore be regarded of inferior validity compared to the pooled aHR estimate. All analyses were performed using R 4.0.3 software (The R Foundation for Statistical Computing, Vienna, Austria; ‘metafor’ package).

Results

Identification of studies

The selection of studies is demonstrated in Fig. 1. The search strategy yielded 3,160 articles. After removal of duplicates (n = 1,044), 2,016 articles remained of which 316 were selected for full text screening. After full text screening, 305 articles were excluded for various reasons (Fig. 1), including lack of a comparative group without PAO-RT (n = 110) or insufficient data in conference abstracts (n = 73). Other major reasons for exclusion were the lack of data on DFS or OS (n = 49) or on a patient group receiving PAO-RT (n = 20). Two studies were excluded because no concurrent chemotherapy was administered [16,25]. One study was excluded because it only included cervical cancer patients without pelvic lymph node metastasis [26]. Cross-referencing did not yield any additional articles. Eleven articles remained eligible for inclusion in the systematic review, of which 3 were appropriate for quantitative meta-analysis with pooling of aHRs. The 8 studies excluded from quantitative analysis reported no HR for DFS.

Study characteristics

Characteristics of the 11 studies included in the literature analysis are summarized in Table 2. Four [27–30] out of 11 studies were prospective by nature and 7 were retrospective [31–37]. No eligible studies published before the year 2014 were found, and 7 out of 11 included studies were published in or after 2016. Most studies reported using MRI [33,34], both CT and MRI [30–32] or a combination of 18F-FDG PET, CT and MRI [27–29,36,37] for nodal staging. In all studies, the majority of patients was treated with concurrent platinum-based chemotherapy. Total radiation dose administered to the para-aortic region ranged from 40 Gy to 50.4 Gy.

Detailed data on pelvic lymph node involvement was available for 10 studies [27,28,30–37] and 3 of those studies only included patients with pelvic lymph node metastasis [30,35,37]. The average proportion of patients with positive pelvic lymph node status in PAO-RT groups versus no-PAO-RT groups across the 11 studies was 69.6% vs. 28.6%, respectively.

Additionally, data on para-aortic lymph node involvement was provided by all 11 studies, and in accordance with the domain of the current review- 10 studies excluded patients with suspicious lymph nodes. One study did include a few patients with suspicious para-aortic lymph nodes [33]. In that study, the proportion of patients with suspicious para-aortic lymph nodes in the PAO-RT group was 11 of 55 (20%) versus none in the no-PAO-RT group [33]. Pathologic (PAO) nodes received a simultaneous integrated boost to 60 Gy in that study [33]. The study was nevertheless included in this review as in its multivariable analysis for DFS the influence of PAO-RT was adjusted for the most distant level of involved lymph nodes.

Crude DFS data were provided in all studies. Three studies [32,33,36] including a total of 1,113 patients provided an adjusted HR.
for DFS and were eligible for quality assessment and quantitative meta-analysis.

Quality assessment

The results of the quality assessment are presented in Fig. 3. Overall, the studies included in the meta-analysis were of moderate quality. All studies included a consecutive series of patients with appropriate exclusion criteria, but moderate concern in patient selection was present in 1 study that included few patients with para-aortic metastases at baseline (but adjusted for this confounder in multivariable analysis) [33]. Selection bias was of particular concern in the studies because patients with positive pelvic lymph node status or a generally higher risk of occult para-aortic lymph node metastases were more likely to receive PAO-RT. However, all 3 studies included in the meta-analysis used multivariable Cox regression analysis in an attempt to adjust for these confounders [32,33,36]. One of these studies in addition attempted to adjust for selection bias due to baseline differences by conducting propensity score matching [36].

There were no reported deviations from intended interventions, and no concerns regarding missing data, classification of interventions or measurement of outcomes. Bias in selection of the reported result was of moderate concern in all 3 studies, as no pre-registered protocol or statistical analysis plan was provided. As such, to some extent the retrospective nature of the studies may have resulted in selective multivariable modelling and reporting of results.

Quantitative synthesis

Three studies provided adjusted HRs for DFS [32,33,36]. All 3 studies were retrospective by nature. In total, 1,113 patients were included, of which 282 (25.3%) received PAO-RT. All 3 studies used a Cox proportional hazards model to adjust for the effect of clinical covariates tumor size and pelvic lymph node metastasis [32], for tumor size, highest level of involved lymph nodes, treatment duration, and nadir-haemoglobin levels [33], or for tumor size, pelvic lymph node metastasis, histology, and FIGO stage [36]. As a separate analysis, 1 study additionally used propensity score matching to adjust for potential confounders, including age, histology, FIGO stage, tumor size, and lymph node involvement [36]. Pooled analysis across the 3 studies that provided an aHR demonstrated a statistically significant beneficial DFS with an overall pooled aHR of 0.87 (95% CI: 0.79–0.97; Fig. 2). The I² statistic revealed no significant heterogeneity in aHR estimates among the 3 studies (I² = 0.0%).

Sensitivity analysis was performed by excluding the 1 study that inappropriately included 11 patients with PAO nodal metastases at baseline [33], although these 11 patients only represented less than 1% of the total 1,113 patients in the primary meta-analysis. Pooling of the 2 remaining studies resulted in a similar overall pooled aHR for DFS of 0.88, but the statistical significance was lost (i.e. 95% CI: 0.61–1.27).

Crude (univariable) survival outcome data as reported in all 11 studies included in this systematic review are summarized in Table 3. At 3 years, median reported DFS among 10 studies was 80.6% versus 71.0% for patients who received PAO-RT versus no PAO-RT, respectively. Weighted for study sample size, the average 3-year DFS across studies was 74.0% versus 70.3%, respectively. At 5 years, median reported DFS among 9 studies was 76.0% versus 68.1%, respectively. Weighted for study sample size, the average 5-year DFS across studies was 72.0% versus 67.3%, respectively. No further quantitative synthesis or significance testing of these studies was performed due to the lack of adjustment for confounders in these estimates.

Discussion

Locally advanced cervical cancer with pelvic lymph node involvement is sometimes associated with occult para-aortic lymph node metastases (PAO-LNM). However, in the current era in which staging techniques have improved and the addition of chemotherapy to radiotherapy is the standard of care, the role of PAO-RT for patients with pelvic lymph node involvement has not been clearly established. In this meta-analysis, pooling of aHRs reported in 3 studies provided evidence that extending the radiation field to cover para-aortic lymph nodes may

---

**Table 2**

Characteristics of studies included for literature analysis.

| Study, year | Design | FIGO stage | n total | n PAO-RT | n no PAO-RT | n (%) PLN + in PAO-RT | n (%) PLN + in no PAO-RT | Mean PAO-RT dose |
|-------------|--------|------------|---------|----------|-------------|------------------------|-------------------------|------------------|
| Al Asiri 2014 [27] | Prosp | IIB-IVA | 74 | 38 | 36 | 23 (60.5) | 15 (41.7) | 45 Gy |
| Liang 2014 [28] | Prosp | IIB-IIIB | 79 | 32 | 47 | 32 (100.0) | 5 (10.6) | 40 Gy |
| Park 2014 [31] | Retro | IIB-IIIB | 203 | 88 | 115 | 59 (67.0) | 34 (29.6) | 45 Gy |
| Yap 2014 [32] | Retro | NR | 228 | 73 | 155 | 46 (63.0) | 21 (13.5) | 40 Gy |
| Kim 2016 [29] | Prosp | IIB-IVA | 114 | 57 | 57 | NR | NR | 45 Gy |
| Ouyang 2017 [33] | Retro | I-III | 107 | 55 | 52 | 44 (80.0) | 25 (48.1) | 45 Gy |
| Lee 2017 [34] | Retro | IIB-IVA | 206 | 96 | 110 | 45 (46.9) | 32 (29.1) | 50.4 Gy |
| Oh 2017 [35] | Retro | IB1-IVA | 126 | 52 | 74 | 52 (100.0) | 74 (100.0) | 45 Gy |
| Wang 2018 [36] | Retro | IIB-IVA | 778 | 154 | 624 | 88 (57.1) | 95 (15.2) | 50.4 Gy |
| Sanders 2021 [37] | Retro | IIB-IVA | 96 | 49 | 47 | 49 (100.0) | 47 (100.0) | 45–50.4 Gy |
| Huang 2021 [30] | Prosp | IIB-IVA | 34 | 17 | 17 | 17 (100.0) | 17 (100.0) | 40–45 Gy |

NR: Not reported. PAO-RT: para-aortic radiotherapy. PLN+: pelvic lymph node metastases. Prosp: prospective. Retro: retrospective.

---

**Fig. 2.** Forest plot of the pooled analysis of 3 studies reporting adjusted HRs of the association of para-aortic radiotherapy versus no para-aortic radiotherapy with disease-free survival.
reduce the risk of disease recurrence over time by 13%, with no evidence of heterogeneity across studies. These pooled HR estimates were adjusted for other prognostic factors within the individual studies. Given the size of the observed beneficial effect of PAO-RT on DFS (pooled aHR 0.87), PAO-RT may be regarded as a tool to improve nodal control, and potentially also distant metastatic control and overall survival as a consequence. The latter suggestion, however, requires additional research ideally in a prospective randomized setting.

The finding that PAO-RT improves DFS raises the question whether staging procedures could be improved for better selection of patients who will benefit. Most studies included in this review used CT or MRI for lymph node staging. However, these imaging modalities used to detect para-aortic lymph node metastases have limited sensitivity [38–40]. In addition, PET-CT was shown to have a low negative predictive value for detecting PAO-LNM [12]. In line with this observation, some studies have reported high rates of upstaging after surgical staging of para-aortic lymph nodes compared to imaging only [12,41,42]. In addition, a large 2010 multi-centre cohort analysis by the FRANCOGYN study group showed that nodal surgical staging had a positive impact on survival in locally advanced cervical cancer patients with no evidence of PAO-LNM on imaging who were treated with chemoradiotherapy [43]. However, surgical staging remains controversial because it has particularly not appeared able to improve the poor survival outcomes of patients with PAO-LNM greater than 5 mm, it could lead to surgical morbidity and a delay in initiating treatment [44,45].

In the majority of cases, PAO-LNM is correlated with positive pelvic lymph nodes as skip metastases are rare [7,46]. Multiple studies demonstrated that cervical cancer patients with pelvic lymph node involvement should be considered at high risk of developing para-aortic lymph node relapse and thus might benefit from elective PAO-RT [44,47,48]. In accordance, the currently ongoing EMBRACE-II multicenter study prescribes addition of PAO-RT in patients with high-risk disease, defined as ≥1 pathologic node at the common iliac level or above, or ≥3 pathologic nodes at any level [11]. Other possible risk factors for developing PAO-LNM might include age, tumour size, FIGO stage and squamous cell carcinoma antigen (SCCA) elevation [49].

Regarding the toxicity of PAO-RT, some recent studies have shown acceptable toxicity rates (6–10% acute grade ≥3 gastro-intestinal (GI) toxicity and 6.5% late grade ≥3 GI toxicity) after PAO-RT with intensity-modulated radiotherapy (IMRT) [50–52]. Conversely, older RTOG trials reported higher rates of toxicity (14–49% grade ≥3 toxicity) [6,53]. However, this may be due to the used 2D radiotherapy technique that is now considered obsolete [54]. Modern radiotherapy techniques, including IMRT and image-guided adaptive radiotherapy, are associated with lower rates of acute and late toxicity [51]. The overall volume irradiated to 43 Gy is strongly associated with bowel morbidity, and can be lowered most effectively by omitting PAO-RT, but in case of PAO-RT by using IMRT instead of 3D conformal RT [11,20]. As such, in light of the findings of this meta-analysis, individualized PAO-RT using modern radiotherapy techniques can be considered in...
contemporary practice with acceptable toxicity risks.

Future directions in the management of PAO-LNM from cervical cancer include optimization of both systemic therapy and radiotherapy and patient selection for PAO-RT. A large recent trial demonstrated that systemic therapy intensification by adjuvant chemotherapy after standard cisplatin-based chemoradiotherapy in patients with locally advanced cervical cancer unfortunately did not improve DFS or OS [55]. Intensification through the addition of immunotherapy as an induction, concurrent and/or adjuvant regimen with chemoradiotherapy is under investigation in multiple ongoing studies (e.g. ATEO-LACC [NCT03612791], COLIBRI [NCT04256213], NICO [NCT03298893]), including 2 large multicenter phase III randomized trials (i.e. CALLA [NCT03830866] and GOG-3047 [NCT04221945]). RT may be further optimized by reducing the dose to organs-at-risk using intensity-modulated proton therapy (IMPT), which might yield particular benefits in patients undergoing PAO-RT. This approach of proton therapy is currently under investigation, for example in the PROTECT trial [56]. Patient selection for PAO-RT may be improved by recently developed nomograms that predict PAO nodal failure [57,58]. In addition, ongoing research is exploring if the prediction accuracy of such nomograms could be improved by studying molecular tumor profiles or extracting imaging features with radiomics or deep learning techniques [59–61].

A few limitations apply to this review. The findings are impacted by the biases and limitations of the included studies. First, unfortunately not all studies comparing PAO-RT to no PAO-RT provided adjusted HRs, which is required for formal meta-analysis. Second, the 3 studies included in the meta-analysis adjusted for prognostic factors differently, which may have impacted the adjusted HRs of the effect of PAO-RT on DFS to some extent. Third, due to the small number of studies appropriate for quantitative meta-analysis, and the lack of individual patient data availability, no subgroup analyses could be performed. Fourth, as for the literature analysis, some articles lacked detailed information on pelvic and/or para-aortic lymph node involvement, which may have led to unreliable results since an unreported variation in the proportions of positive nodes could cause different outcomes.

In conclusion, this meta-analysis of 3 studies suggests a significant association between elective para-aortic lymph node irradiation and improved DFS in cervical cancer patients with pelvic lymph node metastases who undergo primary (chemo)radiotherapy (pooled aHR 0.86). Literature review of 8 additional studies that compared PAO-RT to no PAO-RT (but were not eligible for quantitative synthesis) confirmed this trend of a beneficial impact on DFS by PAO-RT. One approach to deal with unreliable results since an unreported variation in the proportions of positive nodes could cause different outcomes.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Arbryan M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020;8(2):e191–203.

[2] Michel G, Morice F, Castaigne D, Leblanc M, Roy A, Devillard P. Lymphatic spread in stage Ib and II cervical carcinoma: anatomy and surgical implications. Obstet Gynecol 1998;91:360–3.

[3] Ring KL, Young JL, Dunlap NE, Andersen WA, Schneider BF. Extended-field radiation therapy with whole pelvic radiotherapy and cisplatin chemosensitization in the treatment of IB2-IIIB cervical carcinoma: a retrospective review. Am J Obstet Gynecol 2009;201. 109.e1–109.e6.

[4] Huang Y-Y, Wang C-J, Chen H-C, Fang F-M, Huang Y-J, Wang C-Y, et al. Multivariate analysis of para-aortic lymph node recurrence after definitive radiotherapy for stage IB-IIA squamous cell carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 2008;72(3):834–42.

[5] Liang J-A, Chen S-W, Chang W-C, Hang Y-C, Yeh I-S, Yang S-N, et al. Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results. Clin Oncol (R Coll Radiol) 2008;20(9):663–9.

[6] Fujita W, Winter K, Mendenhall M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90–01. J Clin Oncol 2002;20(35):872–80.

[7] Sakuragi N, Satoh C, Takeda N, Hareyama H, Takeda M, Yamamoto R, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer (2000) 97:1547–54.

[8] Nomden CN, Potter R, de Leeuw AAC, Tanderup K, Lindegaard JC, Schmid MP, et al. Nodal failure after chemoradiotherapy and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. Radiat Oncol 2019;14:85–90.

[9] de Gregorio A, Widschwendter M, Ehrer F, Friedt T, Huober J, Janni W, et al. Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histopathologically Confirmed Cases with FIGO Stages IA to IIB. Oncology 2020;98(5):1–9.

[10] Peters M, de Leeuw AAC, Nomden CN, Tanderup K, Kirchheiner K, Lindegaard JC, et al. Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis. Radiol Oncol 2021;5:15.

[11] Potter R, Tanderup K, Kirisits C, de Leeuw A, Kirchheiner K, Nout R, et al. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 2019;8:48–60.

[12] Theilissen AAJ, Jürgenliemk-Schulz IM, van der Leij F, Peters M, Geresteen CG, Zweemer RP, et al. Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis. Gynecol Oncol 2022;22(4):1666–75.

[13] Gouy S, Morice P, Narducci F, Uzan C, Gilmore J, Kolesnikov-Gauthier H, et al. Nodal-staging surgery for locally advanced cervical cancer in the era of LET. Lancet Oncol 2012;13(5):e212–20.

[14] Hair C, Pelovic MJ, Gerbaulet A, Horiot JC, Pourquier H, Delouche J, et al. Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol 1988;11(2):101–12.

[15] Jensen NBK, Potter R, Kirisits C, Fokdal L, Lindegaard JC, Kirisits C, et al. Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. Radiat Oncol 2018;13(2):431–9.

[16] Rotman M, Pajak TF, Choi K, Cley M, Marcial V, Grigsby PW, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IA and IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79–20. JAMA 1995; 274:847–93.

[17] Schmid MP, Frankenhaeuser M, Kirchheiner K, Sturzdaj A, Georg P, Dorr W, et al. Distant metastasis in patients with cervical cancer after primary radiotherapy or with without chemotherapy and image guided adaptive brachytherapy. Gynecol Oncol 2014;134(1):33–42.

[18] Forin I, Jürgenliemk-Schulz I, Mahantheshetty UM, Haie-Meder C, Hoskin P, Segedin B, et al. Distant Metastases in Locally Advanced Cervical Cancer Pattern of Relapse and Prognostic Factors: Early Results From the EMBRACE Study. Int J Radiat Oncol Biol Phys 2015;93(3):S8–9.

[19] Page MJ, McKenzie JE, Bossuyt PM, Bronston I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372. e1.

[20] Potter R, Tanderup K, Schmid MP, Jürgenliemk-Schulz I, Haie-Meder C, Fokdal LU, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 2021;22(4):438–47.

[21] Higgins JPT, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Camppton M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019. p. 143–76.

[22] Steene JA, Henman MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355. i719.

[23] McGuinness LA, Higgins JPT. Risk-of-bias VISualisation (robvis): an R package and shiny web app for visualising risk-of-bias assessments. Res Synth Methods 2021;12(1):55–61.

[24] Deeks JH, Higgins JPT, Altman DG. on behalf of the Cochrane Statistical, Methods Group. Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Camppton M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019. p. 241–538.

[25] Kobayashi T, Tsuchiya H, Ueda A, Miyatake T, Sato T, et al. Technical challenges of prostate and pelvic MRI-guided brachytherapy for patients with positive pelvic lymph nodes. Med. Radiother 2014;27(1):12–20.

[26] Meng Q, Liu X, Wang W, Hou X, Liu X, Sun S, et al. Evaluation of the efficacy of extended-field irradiation in the concurrent chemoradiotherapy

Clinical and Translational Radiation Oncology 35 (2022) 97–103
treatment of locally advanced cervical cancer, stage IIIb in the 2018 FIGO classification. Radiat Oncol 2019;14(1).

[27] Asti MA, Tunic MA, Mohamed R, Bayoumi Y, Alhadad A, Saleh RM, et al. Is extended-field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer? Cancer Manag Res 2014;6:339–46.

[28] Liang J-A, Chen S-W, Hung Y-C, Yeh L-S, Chang W-C, Lin W-C, et al. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIb cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes. Int J Gynecol Cancer 2014;24(5):901–7.

[29] Kim JH, Kim J-Y, Yoon MS, Kim YS, Lee JH, Kim HJ, et al. Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high c-TP53 expression (ROG 07-01): A randomized, open-label, multicenter, phase 2 trial. Radiother Oncol 2016;120(3):383–9.

[30] Huang X, Fang M, Zhu L, Gu C, Cai H, Yang C, et al. Clinical Evaluation of Prophylactic Extended-Field Intensity-Modulated Radiation Therapy with Synchronous Chemotherapy in Locally Advanced Cervical Cancer. Med Sci Monit 2021;27:e904579.

[31] Park SG, Kim JH, Oh YK, Byun SJ, Kim MY, Kwon SH, et al. Is Prophylactic Irradiation to Para-Aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary? Cancer Res Treat 2014;46(4):374–82.

[32] Yap ML, Cuartero J, Yan J, Fustanelli M, Fyles A, Levin W, et al. The role of elective para-aortic lymph node irradiation in patients with locally advanced cervical cancer. Clin Oncol (R Coll Radiol) 2014;26(12):797–803.

[33] Ouyang Y, Wang Y, Chen K, Cao X, Zeng Y. Clinical outcome of extended-field irradiation vs. pelvic irradiation using intensity-modulated radiotherapy for cervical cancer. Oncol Lett 2017;14:7069–76.

[34] Lee J, Lin J-H, Chang C-L, Jan Y-T, Sun F-J, Wu M-H, et al. Prophylactic lower para-aortic irradiation using intensity-modulated radiotherapy mitigates the risk of para-aortic recurrence in locally advanced cervical cancer: A 10-year institutional experience. Gynecol Oncol 2017;164(1):20–6.

[35] Oh J, Seol KH, Lee JH, Choi YS, Park JY, Bae JH. Prophylactic extended-field irradiation with concurrent chemotherapy for pelvic lymph node-negative cervical cancer. Radiat Oncol J 2017;35(4):349–58.

[36] Wang W, Liu X, Meng Q, Zhang F, Hu Ke. Prophylactic Prostatic Lengthened Field Irradiation for Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy: A Propensity-Score Matching Analysis. Int J Gynecol Cancer 2018;28(8):1584–91.

[37] Sanders JC, Muller DA, Dutta SW, Corriher TJ, Ring KL, Showalter TN, et al. Aortic Nodal Radiation in the Definitive Management of Node-Positive Cervical Cancer. Med Sci Monit 2015;21:4097.

[38] Choi HJ, Ju W, Myung SK, Kim Y. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci 2010;101(1):471–9.

[39] Delara R, Yang J, Buckner-Petty S, Magtibay P, Butler K. Surgical or imaging lymph node assessment in locally advanced cervical cancer: a systematic review and meta-analysis. J Gynecol Oncol 2020;31:79.

[40] del Pino M, Fustanelli M, Pahija J, Revoredo A, Martínez-Serrano MJ, Martínez-Román S, et al. Laparoscopic lymphadenectomy in advanced cervical cancer: prognostic and therapeutic value. Int J Gynecol Cancer 2013;23(9):1675–83.

[41] Marszinski S, Kohler C, Roth C, Fuller J, Hinkebein W, Schneider A. Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer? Gynecol Oncol 2005;99(3):536–44.

[42] Dahi V, Simon V, Carpineto X, Bendifallah S, Ouldamer L, Lavoue V, et al. Therapeutic value of surgical paraaortic staging in locally advanced cervical cancer: a multicenter cohort analysis from the FRANCOGYN study group. J Transl Med 2018;16(1).

[43] Gooy S, Morrice P, Narducci F, Uzan C, Martinez A, Rey A, et al. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. J Clin Oncol 2013;31(24):3026–33.

[44] Lai C-H, Huang K-G, Hong J-J, Lee C-L, Chou H-H, Chang T-C, et al. Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer. Gynecol Oncol 2003;90(1):160–7.

[45] Bans A-S, Mathur P, Bhuendar N, Orlaguet J, Mery E, Zerdoud S, et al. The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOLY study. Ann Surg Oncol 2013;20(2):413–22.

[46] Kodaira T, Fowa N, Nakamichi T, Tachibana H, Nakamura T, Tomita N, et al. Prospective study of alternating chemoradiotherapy consisting of extended-field dynamic conformal radiotherapy and systemic chemotherapy using 5-FU and nedaplatin for patients in high-risk group with cervical carcinoma. Int J Radiat Oncol Biol Phys 2009;73(3):351–8.

[47] Gong J-H, Tsai C-S, Lai C-H, Chang T-C, Wang C-C, Chou H-H, et al. Risk stratification of patients with advanced squamous cell carcinoma of cervix treated by radiotherapy alone. Int J Radiat Oncol Biol Phys 2005;63(2):492–9.

[48] Han X, Wen H, Xu J, Chen X, Ke G, Zhou Y, et al. Predictive factors of para-aortic lymph nodes metastasis in cervical cancer patients: a retrospective analysis based on 723 para-aortic lymphadenectomy cases. Oncotarget 2017;8(31):51840–7.

[49] Xu KM, Rajagopalan MS, Kim H, Berial S. Extended field intensity-modulated radiation therapy for gynecologic cancers: Is the risk of duodenal toxicity high? Pract Radiat Oncol 2015;5(4):e291–7.

[50] Poorvu PD, Savoldi CA, Towanmchai K, Damato AL, Viswanathan AN. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2013;85(5):1262–6.

[51] Gupta M, Chopra S, Kandur S, Dheera A, Sampathirao D, Engineer R, et al. Early toxicity and treatment outcomes of extended-field intensity modulated radiotherapy for cervical cancer patients with para-aortic nodal metastasis. Ecameranecsmcience2019;13:957.

[52] Grigby PW, Lu JD, Mutch DG, Kim RY, Eifel PJ. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92–10. Int J Radiat Oncol Biol Phys 1998;41(4):817–22.

[53] Saynaglu Z, Gomes ML, Calabara VF, Leitão MM, Baloiço G. Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta-analysis of randomized clinical trials. Gynecol Oncol 2017;148(2):312–20.

[54] Mileshkin LR, Moore KN, Barnes E, Gebski V, Narayan K, Bradshaw N, et al. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274). JCO 2021;39(18_suppl):LBA34.

[55] Corbeau A, Nout RA, Mens JWM, Horeweg N, Godart J, Kerkhof EM, et al. PROTECT: Prospective Phase-II Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System. Cancers (Basel) 2021;13(22):5748.

[56] Shim S-H, Kim D-Y, Lee SJ, Kim S-N, Kang S-B, Lee S-W, et al. Prediction model for para-aortic lymph node metastasis in patients with locally advanced cervical cancer. Gynecol Oncol 2017;14(4):406–5.

[57] Wang W, Liu X, Meng Q, Zhang F, Hu Ke. Nomogram for predicting para-aortic lymph node metastases in patients with cervical cancer. Arch Gynecol Obstet 2018;298(2):381–8.

[58] Al Y, Zhu H, Xie C, Jin X. Radiomics in cervical cancer: Current applications and future potential. Crit Rev Oncol Hematol 2020;152:102985.

[59] Lai C-H, Huang K-G, Hong J-J, Lee C-L, Chou H-H, Chang C-C, et al. Randomized trial of surgical staging (extraperitoneal or laparoscopic) versus clinical staging in locally advanced cervical cancer. Gynecol Oncol 2003;90(1):160–7.

[60] Wu Q, Wang S, Zhang S, Wang M, Ding Y, Fang J, et al. Development of a Deep Learning Model to Identify Lymph Node Metastasis on Magnetic Resonance Imaging in Patients With Cervical Cancer. JAMA Netw Open 2020;3(7):e2011625.

[61] Fleischmann M, Chatzikonstantinou G, Fokas E, Wichmann J, Christiansen H, Strebbhardt K, et al. Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancers. Cancers (Basel) 2021;13(22):5748.